Description_x000D_ General description_x000D_ β -galactoside α -2, 6-sialyltransferase 1 (ST6GAL1), is a type II membrane protein expressed mainly in the Golgi apparatus. It is encoded by the gene mapped to human chromosome 3q21-28._x000D_ Immunogen_x000D_ The antiserum was produced against synthesized peptide derived from human ST6GAL1._x000D_ Immunogen Range: 171-220_x000D_ Physical form_x000D_ Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ β -galactoside α -2, 6-sialyltransferase 1 (ST6GAL1) plays a vital role in transferring sialic acid from cytidine-monophosphate (CMP)-sialic acid onto galactose-containing substrates. ST6GAL1 has an essential role in the regulation of pluripotency and differentiation in human pluripotent stem cells (hPSCs). The encoded protein functions as important regulator of cell survival in several cell death pathways. Overexpression of this enzyme is observed in various cancers, including colon, breast, and epithelial tumor types. Increased expression of ST6GAL1 might affect cell motility and invasion. ST6GAL1 promoter hypermethylation results in loss of ST6GAL1 expression, therefore ST6GAL1 is considered to have a tumor suppressive role of in human bladder carcinogenesis._x000D_ Features and Benefits_x000D_ Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.